BerGenBio

Selective AXL inhibitors

Home  /  Pipeline

Pipeline

BerGenBio is focused on developing  a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. 

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.